Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce a major milestone in the commercialisation of its predictive test for diabetic kidney disease, PromarkerD, with the US Centers for Medicare & Medicaid Services.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce its latest results for its novel blood test for oesophageal adenocarcinoma will be presented tomorrow at the 19th ISDE World Congress for Esophageal Diseases.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that its subsidiary OxiDx Pty Ltd has been granted a patent in Japan for its platform technology to measure oxidative stress.
It has been a pivotal year for Proteomics International Laboratories Ltd (ASX:PIQ), with the signing of a landmark deal to bring our PromarkerD test for diabetic kidney disease to patients in the United States.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at the 17th Bioshares Biotech Summit on 25 July 2023.